Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

KaNDy Therapeutics is a clinical-stage company focused on the development of NT-814, a novel therapeutic agent targeting menopausal symptoms. The company aims to provide an effective treatment option for women experiencing vasomotor symptoms, such as hot flashes, by leveraging the unique pharmacological properties of NT-814.

Nalu Medical provides a battery‑free neurostimulation system for chronic peripheral nerve pain, consisting of a subcutaneous microstimulator and a wearable therapy disc that wirelessly delivers and programs low‑amplitude electrical pulses. The modular design enables precise nerve targeting, real‑time parameter adjustment, and firmware upgrades without additional surgery, and the implant can be removed in a minor outpatient procedure.

Relief Cardiovascular develops a transcatheter smart implant—the Relief System—to autonomously monitor and modulate inferior vena cava flow for chronic heart‑failure patients with diuretic‑resistant congestion. The implant provides continuous preload adjustment, aiming to improve renal perfusion, reduce hospitalizations, and enable personalized hemodynamic therapy. The company generates revenue through device sales and associated monitoring services once the system receives regulatory clearance.

Wondr Medical is a platform designed for healthcare professionals that facilitates medical discovery through advanced data analysis and imaging technologies. It addresses the need for efficient access to specialized knowledge and resources in various cardiology fields, enhancing clinical decision-making and patient care.